The OxyElite Pro lawsuit represents one of the most significant health and safety crises in the dietary supplement industry, involving false advertising, undisclosed dangerous ingredients, and serious health consequences for consumers. Over 50 cases of liver failure directly linked to the supplement resulted in multiple deaths, prompting a complete FDA recall and triggering multiple class action settlements totaling millions of dollars. The case against manufacturer USPlabs and retailer GNC continues to expand, with ongoing litigation still accepting new claims as of 2025 from consumers who experienced long-term health complications.
OxyElite Pro was marketed as a weight-loss and performance-enhancement supplement, but the FDA’s investigation uncovered a critical problem: the product contained undisclosed prescription pharmaceutical ingredients, including fluoxetine (the active ingredient in Prozac), aegelene, and DMAA—none of which were listed on the label. For consumers who purchased what they believed to be a natural supplement, the discovery that they had unknowingly ingested prescription antidepressants without medical supervision or informed consent became the basis for widespread legal action. The case serves as a cautionary example of how supplement manufacturers can operate outside normal regulatory oversight.
Table of Contents
- What Triggered the OxyElite Pro Lawsuit?
- The Hidden Pharmaceutical Ingredients in OxyElite Pro
- The FDA Recall and Public Health Response
- The Settlement Agreements and Compensation
- Who Was Liable and Why the Manufacturer Faced Legal Action
- Ongoing Litigation and Emerging Claims
- What This Case Means for Supplement Regulation and Consumer Protection
- Conclusion
What Triggered the OxyElite Pro Lawsuit?
The FDA’s investigation into OxyElite Pro began when health professionals reported an unusual cluster of severe liver injuries among people using the supplement. Between 2010 and 2013, the agency documented over 50 cases of acute liver failure directly attributable to the product, including at least three deaths. Patients reported symptoms ranging from jaundice and abdominal pain to complete liver failure requiring emergency medical intervention.
The severity and pattern of these injuries—all linked to a single supplement product—triggered one of the most aggressive FDA enforcement actions against a dietary supplement in recent history. The root cause became apparent during the FDA’s forensic analysis: OxyElite Pro contained fluoxetine, a prescription antidepressant that had never been disclosed to consumers or approved as an ingredient in dietary supplements. The presence of this pharmaceutical compound, combined with other potentially harmful substances, created an undisclosed health risk that made the supplement fundamentally dangerous. USPlabs had not conducted adequate safety testing, had not disclosed the prescription ingredient to consumers or healthcare providers, and had not ensured that the product was manufactured under controlled conditions that would prevent contamination or undisclosed additives.
The Hidden Pharmaceutical Ingredients in OxyElite Pro
The most alarming discovery during the FDA investigation was that OxyElite Pro contained fluoxetine, an SSRI (selective serotonin reuptake inhibitor) antidepressant typically prescribed under the brand name Prozac. This was not listed on the product label, leaving consumers unaware they were ingesting a prescription medication. Fluoxetine can cause serious side effects including liver toxicity, especially when combined with other ingredients or taken by people with undiagnosed health conditions. For consumers taking other medications or with existing liver disease, the undisclosed presence of fluoxetine created dangerous drug interactions that could trigger the severe liver failures documented in the cases.
Beyond fluoxetine, the FDA identified additional problematic ingredients, including DMAA (dimethylammonium) and aegelene. DMAA, in particular, had already been banned by the FDA in 2013 from dietary supplements due to its association with heart attacks and strokes. The presence of these compounds—combined with the undisclosed pharmaceutical ingredient—indicated that OxyElite Pro had not undergone proper safety testing and that USPlabs had either deliberately concealed the ingredients or had completely failed to maintain quality control over its manufacturing process. This failure to disclose or control ingredients represented a fundamental breach of consumer trust and regulatory compliance.
The FDA Recall and Public Health Response
In April 2013, following mounting evidence of serious liver injuries, the FDA issued a complete recall of all OxyElite Pro products. The agency specifically warned consumers to stop using the supplement immediately and to seek medical attention if they had experienced symptoms such as jaundice, dark urine, abdominal pain, or unexplained fatigue after taking the product. The recall also extended to similar products manufactured by USPlabs that might have contained the same problematic ingredients. This was not a voluntary recall initiated by the manufacturer—it was a mandatory action taken by federal regulators to protect public health.
The recall process revealed another failure in the supply chain: consumers who had already purchased OxyElite Pro were not automatically notified of the dangers. Many people continued taking the supplement for weeks or months after the recall was announced, unaware that the product they had in their medicine cabinet was linked to severe liver disease. Some consumers only learned about the recall when they experienced symptoms serious enough to require hospitalization. This communication failure became part of the basis for false advertising claims—consumers argued that they had relied on USPlabs’ claims of safety and efficacy without knowing the true contents of what they were ingesting.
The Settlement Agreements and Compensation
The legal fallout from the OxyElite Pro case resulted in multiple settlement agreements, each addressing different aspects of the false advertising and breach of warranty claims. In February 2013, USPlabs agreed to pay $2 million to settle the first major class action lawsuit, with individual consumers eligible to receive up to $300 per claim for their purchases and any associated medical expenses. This settlement covered false advertising claims related to the misrepresentation of the product’s contents and safety profile. Additional settlements followed as the litigation expanded. In September 2014, USPlabs and GNC settled a false advertising lawsuit in Florida for $2 million related to both OxyElite Pro and another problematic supplement called Jack3D.
A third settlement in November 2014 (Velasquez v. USPlabs) also resulted in a $2 million agreement in Florida federal court. Most significantly, in December 2016, GNC Holdings Inc. settled with federal investigators for $2.25 million specifically related to misbranding violations and the failure to properly disclose the ingredient issues. These settlements, while substantial, were widely criticized by consumer advocates as inadequate compensation for the lifetime health consequences many consumers faced, particularly those who suffered permanent liver damage or other long-term complications.
Who Was Liable and Why the Manufacturer Faced Legal Action
USPlabs, the manufacturer of OxyElite Pro, was the primary target of litigation because they formulated the product, sourced the ingredients, and made false claims about its safety and contents on the label and in marketing materials. The company either knowingly included prescription pharmaceutical ingredients without disclosure, or failed catastrophically in quality control and oversight of its supply chain—either way, consumers held them accountable for the consequences. USPlabs was explicitly liable for breach of warranty because the product did not meet the basic implied warranty of being safe for human consumption as marketed.
GNC, which retailed OxyElite Pro in its stores and online, shared liability in some cases because they marketed and sold the product while making similar false claims about safety and contents. While GNC’s role was secondary to the manufacturer’s, the retail giant had a responsibility to verify supplier claims and to ensure that products on their shelves met regulatory standards. The settlements involving both entities reflected the principle that companies at every level of the supply chain—manufacturing, distribution, and retail—bear responsibility for ensuring that the products they sell are safe and truthfully labeled. However, it’s important to note that many consumers who suffered serious health consequences felt the settlement amounts were insufficient, especially for those who experienced permanent organ damage requiring ongoing medical treatment.
Ongoing Litigation and Emerging Claims
As of February 2025, Schmidt & Clark LLP continues accepting new OxyElite Pro injury cases across all 50 states on behalf of consumers experiencing long-term health complications from the supplement. Approximately 100 potential claimants have been identified against S.K. Labs and Patel—indicating that the original manufacturers may not have been the only entities involved in the product’s distribution or formulation.
New claims focus on chronic liver disease, permanent organ damage, and ongoing medical complications that extend far beyond the acute liver failure cases documented in the initial FDA investigation. This ongoing litigation reflects an important principle in mass tort cases: as time passes, victims may develop additional complications or receive diagnoses that confirm causation between their supplement use and long-term health damage. Some consumers did not seek immediate legal action after the recall, believing their liver injuries had resolved, only to discover years later that they had developed cirrhosis, chronic hepatitis, or other permanent conditions. The availability of ongoing claims acknowledges that the true harm caused by OxyElite Pro may take years to fully manifest and that justice requires allowing injured parties to pursue compensation even after the initial settlements have been distributed.
What This Case Means for Supplement Regulation and Consumer Protection
The OxyElite Pro case exposed critical gaps in how the supplement industry is regulated compared to pharmaceutical products. Unlike drugs, which require FDA approval before being marketed, supplements are generally assumed to be safe unless the FDA can prove otherwise—a standard that places the burden on regulators rather than manufacturers to demonstrate safety. USPlabs exploited this gap by selling a product with undisclosed pharmaceutical ingredients without submitting it for FDA review or safety testing. The case demonstrated that self-regulation within the supplement industry was insufficient and that manufacturers could operate without adequate oversight.
In the years following the OxyElite Pro scandal, the FDA has increased enforcement actions against supplement manufacturers and has worked to improve manufacturing standards and ingredient disclosure requirements. However, consumer advocates argue that the regulatory framework remains inadequate and that companies still face incentives to cut corners on safety testing and quality control. The OxyElite Pro case serves as a reminder that consumers cannot assume that products on store shelves have been thoroughly vetted for safety, and that supplements claiming to be “natural” or “safe” may contain undisclosed ingredients with serious health risks. For anyone considering supplement use, the case underscores the importance of consulting healthcare providers and being aware that dietary supplements are not subject to the same rigorous pre-market approval process as prescription medications.
Conclusion
The OxyElite Pro lawsuit remains one of the most significant examples of how supplement manufacturers can prioritize profit over consumer safety, resulting in serious health consequences and multi-million-dollar legal settlements. The documented cases of liver failure, the discovery of undisclosed prescription ingredients, the complete FDA recall, and the multiple settlement agreements spanning from 2013 through 2016 established clear accountability for both the manufacturer USPlabs and retailer GNC. Yet for consumers who suffered permanent liver damage, chronic hepatitis, or other long-term complications, the financial settlements provided only partial justice for the lifetime health consequences they continue to face.
If you purchased and used OxyElite Pro and experienced health complications such as liver disease, jaundice, abdominal pain, or other symptoms, you may still have legal options available. Ongoing litigation continues to accept new claims from injured consumers across all 50 states, and the statute of limitations for filing claims may still be available depending on when your injury occurred and which state you reside in. Consulting with an experienced attorney who handles supplement injury cases can help you understand whether you qualify for compensation and what evidence will be needed to support your claim.